Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study

Johan Maertens, George R. Thompson, Andrej Spec, Fariba Donovan, Sarah P. Hammond, Anke H. W. Bruns, Galia Rahav, Shmuel Shoham, Royce W. Johnson, Bart Rijnders, Joanna Schaenman, Martin Hoenigl, Catherine Morrissey, Sanjay R. Mehta, Christopher H. Heath, Philipp Koehler, David L Paterson, Monica A. Slavin, Jesús Fortün, M. Hong Nguyen, Thomas F. Patterson, Olga Uspenskaya, Frank L. van de Veerdonk, Paul E. Verweij, Mickaël Aoun, Aspasia Georgala, Barbara D. Alexander, Methee Chayakulkeeree, Varun Mehra, Marisa H. Miceli, Monica K Sikka, Amparó Solé, Thomas J. Walsh, José María Aguado, Steven M. Holland, Mohamed Moussa, Riina Rautemaa‐Richardson, Rohit Bazaz, Stefan Schwartz, Stephen R. Walsh, Markus Plate, Dana Yehudai-Ofir, Roger J. M. Brüggemann, Oliver A. Cornely, Luis Ostrosky‐Zeichner, José A. Vázquez, P. Lewis White, Karen Cornelissen, Geoffrey G Ross, Lesley Fitton, Aaron Dane, Daniela Zinzi, John Rex, Sharon C.-A. Chen